Barclays’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$111M Buy
565,470
+232,168
+70% +$45.1M 0.03% 460
2025
Q4
$57.8M Buy
333,302
+82,170
+33% +$15M 0.01% 713
2025
Q3
$47.9M Sell
251,132
-105,269
-30% -$18.7M 0.01% 793
2025
Q2
$64M Sell
356,401
-31,098
-8% -$5.4M 0.01% 616
2025
Q1
$65.6M Buy
387,499
+123,145
+47% +$20.2M 0.02% 561
2024
Q4
$39.9M Sell
264,354
-34,568
-12% -$5.38M 0.01% 767
2024
Q3
$46.4M Buy
298,922
+78,980
+36% +$11.8M 0.01% 699
2024
Q2
$30.1M Sell
219,942
-251,453
-53% -$34.4M 0.01% 798
2024
Q1
$62.7M Buy
471,395
+90,244
+24% +$11.7M 0.02% 523
2023
Q4
$52.6M Buy
381,151
+135,687
+55% +$17.8M 0.02% 639
2023
Q3
$29.9M Sell
245,464
-58,210
-19% -$7.76M 0.02% 648
2023
Q2
$42.7M Buy
303,674
+84,859
+39% +$11.7M 0.03% 495
2023
Q1
$31M Sell
218,815
-122,647
-36% -$17.5M 0.01% 671
2022
Q4
$53.4M Buy
341,462
+15,885
+5% +$2.28M 0.02% 465
2022
Q3
$39.9M Buy
325,577
+30,838
+10% +$4.06M 0.04% 375
2022
Q2
$39.2M Sell
294,739
-5,278
-2% -$719K 0.02% 469
2022
Q1
$41.1M Sell
300,017
-13,281
-4% -$1.85M 0.03% 470
2021
Q4
$54.2M Sell
313,298
-79,707
-20% -$12.1M 0.02% 548
2021
Q3
$57.1M Buy
393,005
+52,106
+15% +$7.62M 0.03% 468
2021
Q2
$45M Buy
340,899
+75,011
+28% +$9.82M 0.02% 565
2021
Q1
$34.1M Buy
265,888
+18,587
+8% +$2.29M 0.02% 593
2020
Q4
$29.5M Buy
247,301
+76,823
+45% +$9.37M 0.02% 658
2020
Q3
$19.5M Buy
170,478
+80,993
+91% +$9.57M 0.01% 759
2020
Q2
$10.2M Sell
89,485
-27,374
-23% -$2.9M 0.01% 947
2020
Q1
$9.38M Sell
116,859
-179,815
-61% -$18.6M 0.01% 1023
2019
Q4
$31.7M Buy
296,674
+92,125
+45% +$9.61M 0.02% 712
2019
Q3
$21.9M Sell
204,549
-23,366
-10% -$2.4M 0.01% 828
2019
Q2
$23.2M Buy
227,915
+32,046
+16% +$3.08M 0.01% 837
2019
Q1
$17.6M Buy
195,869
+45,836
+31% +$3.97M 0.01% 921
2018
Q4
$12.5M Sell
150,033
-194,380
-56% -$18.2M 0.01% 1024
2018
Q3
$37.2M Buy
344,413
+142,016
+70% +$15.6M 0.03% 541
2018
Q2
$22.3M Sell
202,397
-71,451
-26% -$7.44M 0.02% 740
2018
Q1
$27.5M Buy
273,848
+37,455
+16% +$3.84M 0.02% 692
2017
Q4
$23.3M Buy
236,393
+67,036
+40% +$6.36M 0.02% 727
2017
Q3
$15.9M Buy
169,357
+59,834
+55% +$6.35M 0.02% 769
2017
Q2
$12.2M Sell
109,523
-35,970
-25% -$3.8M 0.01% 855
2017
Q1
$14.3M Buy
145,493
+66,052
+83% +$6.3M 0.02% 692
2016
Q4
$7.3M Sell
79,441
-17,399
-18% -$1.5M 0.01% 1132
2016
Q3
$8.19M Buy
96,840
+4,584
+5% +$385K 0.01% 983
2016
Q2
$7.51M Buy
92,256
+13,630
+17% +$1.04M 0.01% 1019
2016
Q1
$5.58M Buy
78,626
+31,742
+68% +$2.13M 0.01% 1100
2015
Q4
$3.33M Sell
46,884
-13,416
-22% -$902K ﹤0.01% 1614
2015
Q3
$3.68M Sell
60,300
-19,755
-25% -$1.38M ﹤0.01% 1580
2015
Q2
$5.76M Sell
80,055
-21,278
-21% -$1.57M 0.01% 1387
2015
Q1
$7.7M Sell
101,333
-490
-0.5% -$35.1K 0.01% 1242
2014
Q4
$6.82M Buy
101,823
+19,291
+23% +$1.22M 0.01% 1452
2014
Q3
$4.95M Buy
82,532
+12,252
+17% +$755K ﹤0.01% 1784
2014
Q2
$4.08M Sell
70,280
-73,892
-51% -$4.33M ﹤0.01% 1939
2014
Q1
$8.22M Sell
144,172
-111,821
-44% -$5.99M 0.01% 1299
2013
Q4
$13.6M Sell
255,993
-16,585
-6% -$984K 0.01% 1033
2013
Q3
$16.6M Buy
272,578
+128,710
+89% +$7.7M 0.02% 791
2013
Q2
$8.72M Buy
+143,868
New +$8.57M 0.01% 1179

Other funds holding DGX

Barclays's DGX Position: Q1 2026 in Review

Barclays increased its Quest Diagnostics (DGX) stake by 70% in Q1 2026, buying an estimated $45.1M and bringing the position to 565,470 shares worth $111M. The position accounts for 0.03% of the portfolio, ranked #460.

Barclays first reported a position in DGX in Q2 2013 and has held it in 52 quarters since. 1,066 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Barclays held 565,470 shares of Quest Diagnostics worth $111M as of Q1 2026.
  • Barclays bought 232,168 Quest Diagnostics shares in Q1 2026, an estimated $45.1M.
  • Quest Diagnostics made up 0.03% of Barclays's portfolio in Q1 2026, its #460 holding.
  • Barclays first reported a position in Quest Diagnostics in Q2 2013 and has held it in 52 quarters since.
  • 1,066 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.